News und Analysen
Don't Make This Huge Mistake With Celgene
Several years ago, I started to look seriously at investing in Celgene (NASDAQ: CELG) stock. Someone I knew told me that I probably shouldn't get too excited about the biotech. I'm glad I didn't....
Don't Make This Huge Mistake With Celgene
Several years ago, I started to look seriously at investing in Celgene (NASDAQ: CELG) stock. Someone I knew told me that I probably shouldn't get too excited about the biotech. I'm glad I didn't....
10 Rock-Solid Reasons Johnson & Johnson's Near-Term Future Looks Bright
Johnson & Johnson (NYSE: JNJ) reported anemic overall sales growth in the first half of 2017. The big healthcare company even saw a decline in year-over-year earnings during the period.....
10 Rock-Solid Reasons Johnson & Johnson's Near-Term Future Looks Bright
Johnson & Johnson (NYSE: JNJ) reported anemic overall sales growth in the first half of 2017. The big healthcare company even saw a decline in year-over-year earnings during the period.....
Loxo Oncology's Up 230% in the Past Year -- Can You Still Make Money Buying It?
Loxo Oncology (NASDAQ: LOXO) is one of biotech's best-performing stars this past year, and shares could still have room to run higher if the FDA cooperates with an OK for its lead drug,....
Better Buy: Pfizer Inc. vs. Bristol-Myers Squibb
You can call them "frenemies." Pfizer (NYSE: PFE) and Bristol-Myers Squibb (NYSE: BMY) are friends when it comes to blockbuster blood thinner Eliquis. But the two big pharma companies are enemies....
Better Buy: Pfizer Inc. vs. Bristol-Myers Squibb
You can call them "frenemies." Pfizer (NYSE: PFE) and Bristol-Myers Squibb (NYSE: BMY) are friends when it comes to blockbuster blood thinner Eliquis. But the two big pharma companies are enemies....
3 Stocks to Buy and Hold for Decades
Trading in and out of stocks may be exciting, but it's no way to build wealth. Buying shares of high-quality companies and holding on for the long haul is a far better alternative.We asked three....
3 Stocks to Buy and Hold for Decades
Trading in and out of stocks may be exciting, but it's no way to build wealth. Buying shares of high-quality companies and holding on for the long haul is a far better alternative.We asked three....
Halozyme, Inovalon, and Teva Soared This Week: Can They Go Higher?
Many healthcare stocks muddled along over the past week. That wasn't the case, though, for three stocks of companies operating in very different parts of the healthcare spectrum.Shares of Halozyme....
Is ImmunoGen Running Out of Steam, or Taking a Breather?
There's good news and bad news for ImmunoGen (NASDAQ: IMGN) shareholders. The good news is that the biotech stock is up more than 230% so far in 2017. The bad news? Shares have dropped nearly 20%....
Which of These 5 Will Be the Best-Selling Drug Worldwide in 2020?
The global pharmaceutical industry is a giant, in case you didn't already know it. According to a 2016 report from the International Trade Administration (ITA), global sales of pharmaceuticals are....
Which of These 5 Will Be the Best-Selling Drug Worldwide in 2020?
The global pharmaceutical industry is a giant, in case you didn't already know it. According to a 2016 report from the International Trade Administration (ITA), global sales of pharmaceuticals are....
The Smartest Move Johnson & Johnson Has Made All Year
Healthcare conglomerate Johnson & Johnson (NYSE: JNJ) is what you might call a stalwart in the portfolios of risk-averse, income-seeking long-term investors. It's about as rock-solid as they....
The Smartest Move Johnson & Johnson Has Made All Year
Healthcare conglomerate Johnson & Johnson (NYSE: JNJ) is what you might call a stalwart in the portfolios of risk-averse, income-seeking long-term investors. It's about as rock-solid as they....
Why Abeona Therapeutics Inc Stock Jumped Higher Today
Shares of Abeona Therapeutics (NASDAQ: ABEO) are up 18% as of 2:50 p.m. EDT after an analyst from RBC Capital initiated coverage of the gene therapy company with an outperform rating and assigned....
Here's What Caused Arrowhead Pharmaceuticals' Stock to Spike Today
After Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced Thursday that it has crafted a new drug development platform, and created a handful of candidate compounds, shares of the clinical-stage....
Of the 14 Largest Marijuana Stocks, Only These 2 Are Down Over the Past Year
The stock market has been on a tear since hitting a trough in March 2009, but in recent years it's marijuana stocks that have headed to the front of the class, so to speak. Back in June, we looked....
3 Biotech Stocks I'd Buy Right Now
It's been a banner year so far for biotech, but a handful of stocks have been travelling in the opposite direction of the iShares Nasdaq Biotechnology index. The industry-tracking index has risen....
Pfizer Punches Back at Johnson & Johnson in Prostate Cancer
After winning Food and Drug Administration (FDA) approval for use in castration-resistant metastatic prostate cancer in 2012, Pfizer's (NYSE: PFE) Xtandi quickly gained ground on Johnson &....
Pfizer Punches Back at Johnson & Johnson in Prostate Cancer
After winning Food and Drug Administration (FDA) approval for use in castration-resistant metastatic prostate cancer in 2012, Pfizer's (NYSE: PFE) Xtandi quickly gained ground on Johnson &....
3 Reasons Why Gilead Sciences Stock Is a Buy Now
Gilead Sciences (NASDAQ: GILD) is a biotech behemoth, but its shares have fallen on tough times because hepatitis C sales are slipping. While headwinds in hepatitis C remain, the company's recent....
3 Reasons Why Gilead Sciences Stock Is a Buy Now
Gilead Sciences (NASDAQ: GILD) is a biotech behemoth, but its shares have fallen on tough times because hepatitis C sales are slipping. While headwinds in hepatitis C remain, the company's recent....
3 Reasons Why Gilead Sciences Stock Is a Buy Now
Gilead Sciences (NASDAQ: GILD) is a biotech behemoth, but its shares have fallen on tough times because hepatitis C sales are slipping. While headwinds in hepatitis C remain, the company's recent....
Who Will Win the Kidney Cancer Battle Between Bristol-Myers Squibb and Exelixis?
A head-to-head competition for market share in the renal cell carcinoma (RCC) market appears to be about to intensify. In one corner is Bristol-Myers Squibb (NYSE: BMY). With a market cap of over....